ASH was as always hectic and stimulating. The CML oral sessions are very well summarized in the link from iCMLf below. Nothing very new here. The role of ASXL1 mutations are is maybe clarifying a bit. New drugs TERN and ELVN-1 are interesting and may become available in company studies in the Nordics
iCMLf – Session Summaries from the 67th ASH Annual Meeting – About us | International CML Foundation
BosuPeg first presentation
The BosuPeg poster was well received but with relatively modest attention. We must now try to get data published as an article soon. The commercial medical press made a few interviews with me links below.
Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights